<SEC-DOCUMENT>0001144204-19-024240.txt : 20190507
<SEC-HEADER>0001144204-19-024240.hdr.sgml : 20190507
<ACCEPTANCE-DATETIME>20190507161626
ACCESSION NUMBER:		0001144204-19-024240
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20190501
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190507
DATE AS OF CHANGE:		20190507

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOANALYTICAL SYSTEMS INC
		CENTRAL INDEX KEY:			0000720154
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				351345024
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23357
		FILM NUMBER:		19803331

	BUSINESS ADDRESS:	
		STREET 1:		2701 KENT AVE
		CITY:			WEST LAFAYETT
		STATE:			IN
		ZIP:			47906-1382
		BUSINESS PHONE:		3174634527

	MAIL ADDRESS:	
		STREET 1:		2701 KENT AVENUE
		CITY:			WEST LAFAYETTE
		STATE:			IN
		ZIP:			47906-1382
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv520883_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE
COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C.
20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM
8&ndash;K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Section
13 or 15 (d) of the<BR>
 Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of Earliest
Event Reported): May 1, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 14pt"><B>Bioanalytical
Systems, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact Name of Registrant
as Specified in Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Indiana</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or Other Jurisdiction of Incorporation)</P></TD>
    <TD STYLE="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>0-23357</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Commission File Number)</P></TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>35-1345024</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer Identification No.)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2701 Kent Avenue</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>West Lafayette, Indiana</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Address of Principal Executive Offices)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.2pt"><B>47906-1382</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.15pt">(Zip Code)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>(765) 463-4527</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>N/A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former Name or Former Address, if Changed
Since Last Report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Securities registered pursuant to Section
12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; padding: 0; font-size: 10pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="width: 30%; padding: 0; font-size: 10pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading Symbol(s)</FONT></TD>
    <TD STYLE="width: 40%; padding: 0; font-size: 10pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of each exchange where registered</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; font-size: 10pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Shares</FONT></TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BASi</FONT></TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NASDAQ Capital Market</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 1.01 Entry into a Material Definitive Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Acquisition</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 1, 2019, Bioanalytical Systems,
Inc. (the &ldquo;Company&rdquo;), through its wholly-owned subsidiary Oriole Toxicology Services LLC (the &ldquo;Purchaser&rdquo;),
acquired (the &ldquo;Acquisition&rdquo;) from Smithers Avanza Toxicology Services LLC (the &ldquo;Seller&rdquo;), a consulting-based
contract research laboratory located in Gaithersburg, Maryland, substantially all of the assets used by the Seller in connection
with the performance of in-vivo mammalian toxicology CRO services for pharmaceuticals (small molecules and biologics), vaccines,
agro and industrial chemicals, under the terms and conditions of an Asset Purchase Agreement, dated May 1, 2019, among the Purchaser,
the Company, the Seller and the member of the Seller (the &ldquo;Purchase Agreement&rdquo;). The consideration for the Acquisition
consisted of $1,270,646.10 in cash, subject to certain adjustments and an indemnity escrow of $125,000, 200,000 of the Company&rsquo;s
common shares and an unsecured promissory note in the initial principal amount of $810,000 made by Purchaser and guaranteed by
the Company. The Company funded the cash portion of the purchase price for the Acquisition with cash on hand and the net proceeds
from the refinancing of its credit arrangements with First Internet Bank (&ldquo;FIB&rdquo;), as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Purchase Agreement contains customary
representations, warranties, covenants (including non-competition requirements applicable to the selling parties for a 5 year period)
and indemnification provisions. As contemplated by the Purchase Agreement, on May 1, 2019 the Purchaser assumed amended lease arrangements
for certain premises in Gaithersburg, Maryland (the &ldquo;Lease Arrangements&rdquo;). Under the Lease Arrangements, the Purchaser
agreed to lease the premises for a term of 5 years and 8 months, with two 5 year extensions at Purchaser&rsquo;s option. Annual
minimum rental payments under the initial term of the Lease Arrangements range from $400,000 to $800,000, provided that the Lease
Arrangements provide the Purchaser with the option to purchase the premises. The Lease Arrangements include customary rights upon
a default by landlord or tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>Amendment to Credit Arrangements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Acquisition, on
May 1, 2019 the Company and FIB entered into a fourth amendment (the &ldquo;Fourth Amendment&rdquo;) to the Credit Agreement by
and between the parties dated June 23, 2017, as previously amended July 2, 2018, September 6, 2018 and September 28, 2018 (as amended,
the &ldquo;Credit Agreement&rdquo;) to (i) extend the term of the Company&rsquo;s $3,500,000 revolving credit facility to June
30, 2020, (ii) provide the Company with an additional term loan (the &ldquo;New Term Loan&rdquo;) in the amount of $1,270,641.10,
the proceeds of which were used to fund the cash consideration for the Acquisition, and (iii) provide for an additional line of
credit in the principal amount of $1,100,000 (the &ldquo;Capex Line&rdquo;), which the Company may borrow from time to time, subject
to the terms of the Credit Agreement. The New Term Loan and the Capex Line mature November 1, 2025 and June 30, 2020, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amounts outstanding under the New Term
Loan bear interest at a fixed per annum rate of 4.63%, while interest accrues on the principal balance of the Capex Line at a floating
per annum rate equal to the sum of the Prime Rate plus Fifty Basis Points (0.5%), which rate shall change concurrently with the
Prime Rate. Commencing June 1, 2019, the New Term Loan requires monthly interest only payments until December 1, 2019, from which
time payments of principal and interest in monthly installments equal to $20,288.97 become due, with all accrued but unpaid interest,
cost and expenses due and payable at the maturity date. The Company is required to pay accrued but unpaid interest on the Capex
Line on a monthly basis commencing on June 1, 2019, until June 30, 2020, at which time the entire balance of the Capex Line, together
with accrued but unpaid interest, costs and expenses, shall be due and payable in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following its amendment, the Company&rsquo;s
obligations under the Credit Agreement are guaranteed by BAS Evansville, Inc. (&ldquo;BASEV&rdquo;), Seventh Wave Laboratories,
LLC (&ldquo;Seventh Wave&rdquo;), as well as the Purchaser, each a wholly owned subsidiary of the Company. The Company&rsquo;s
obligations under the Credit Agreement and BASEV&rsquo;s, Seventh Wave&rsquo;s and the Purchaser&rsquo;s obligations under their
respective Guaranties are secured by first priority security interests in substantially all of the assets of the Company, BASEV,
Seventh Wave and the Purchaser respectively, as well as mortgages on the Company&rsquo;s and BASEV&rsquo;s facilities in West Lafayette,
Indiana and Evansville, Indiana, respectively, and pledges of the Company&rsquo;s ownership interests in its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The various restrictive covenants under
the Credit Agreement remain consistent, provided that the parties agreed (i) to modify the computation of the minimum debt service
coverage ratio and lower the ratio itself during certain periods to 1.15 to 1.0 or 1.20 to 1.0 to appropriately reflect relevant
aspects of the Acquisition and (ii) to suspend application of the cash flow coverage ratio through the fiscal quarter ending December
31, 2019, with the ratio of the Company&rsquo;s total funded debt (as defined in the Credit Agreement) as of the last day of each
fiscal quarter to its EBITDA (as defined in the Credit Agreement) for the 12 months ended as of March 31, 2020 and June 30, 2020
not to exceed 5.00 to 1.00 and 4.50 to 1.00, respectively. The Company also agreed to obtain a life insurance policy in an amount
not less than $2,000,000 for its President and Chief Executive Officer and to provide FIB an assignment of such life insurance
policy as collateral.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing descriptions of the Purchase
Agreement, the Fourth Amendment and the Lease Arrangements do not purport to be complete and are qualified in their entirety by
the terms and conditions of those agreements, copies of which will be filed as exhibits to the Company&rsquo;s Quarterly Report
on Form 10-Q for the period ending June 30, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 2.01 Completion of Acquisition
or Disposition of Assets.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information included in Item 1.01 of
this Current Report on Form 8-K is incorporated by reference into this Item 2.01.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 2.03 Creation of a Direct Financial
Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information set forth in Item 1.01
with respect to the Fourth Amendment and the Lease Arrangements is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 3.02 Unregistered Sales of Equity
Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Purchase Agreement, the
Company issued 200,000 of the Company&rsquo;s common shares to the Seller. The shares were issued in reliance upon the exemption
from the registration requirements of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), provided by Section
4(a)(2) of the Securities Act as sales by an issuer not involving any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information set forth in Item 1.01
with respect to the Acquisition is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 7.01 Regulation FD Disclosure.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 1, 2019 and May 7, 2019, the Company
issued press releases relating to the Acquisition, the corrected copy of which is attached to this Current Report on Form 8-K as
Exhibit 99.1 and is incorporated herein by reference. This information shall not be deemed &ldquo;filed&rdquo; for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or incorporated by reference in
any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a
filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <B>Item 9.01</B> <B>Financial Statements and Exhibits</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The financial statements and pro forma financial information
with respect to the Acquisition required by Item 9.01 of Form 8-K will be included in an amendment to this Form 8-K by not later
than 71 calendar days after the date that the initial report on Form 8-K is required to be filed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 3%; text-align: left">(d)</TD><TD STYLE="text-align: justify; width: 92%"><I>Exhibits</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 15%; padding: 0; font-size: 10pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit Number</FONT></TD>
    <TD STYLE="width: 77%; padding: 0; font-size: 10pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-indent: 0"><A HREF="tv520883_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-indent: 0"><A HREF="tv520883_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Copy of press release, dated May 1, 2019, as corrected May 7, 2019, issued by the Company.</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I>&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 4.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Bioanalytical Systems, Inc. </B></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 50%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 3%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 30%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 17%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: May 7, 2019</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jill C. Blumhoff</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Jill C. Blumhoff</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: CFO and VP Finance</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 4.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv520883_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; padding: 0; text-indent: 0">
        <IMG SRC="image_001.jpg" ALT=""><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>
        <P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>
        <P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P></TD>
    <TD STYLE="width: 55%; padding: 0; font-size: 10pt; text-align: right; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt">NEWS RELEASE</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 70%; padding: 0; font-size: 10pt; text-align: right; text-indent: 0"><B>FOR MORE INFORMATION:</B></TD>
    <TD STYLE="width: 30%; padding: 0; font-size: 10pt; text-align: right; text-indent: 0"><B>BASi Company Contacts:</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Joe Flynn</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Chief Commercial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Phone: 314.882.2218</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><U>jflynn@BASinc.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Jill C. Blumhoff</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Phone: 765.497.8381</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><U>jblumhoff@BASinc.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Smithers Company Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">David L. Schwarz</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Vice President</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Marketing and Strategic Planning</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Phone: 330.762.7441</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><U>dschwarz@smithers.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>CORRECTED
PRESS RELEASE: BASi Acquires the Smithers Avanza<BR>
 Toxicology Services Business Unit to Support Growing Toxicology Business<BR>
 and
Broaden Scientific Talent</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">WEST LAFAYETTE, Ind., May 7, 2019 --&nbsp;This press release
corrects a prior version published on May 1, 2019, and is updated to revise the amount of one of the loans previously reported.
The corrected release reads:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<IMG SRC="image_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>BASi Acquires
the Smithers Avanza Toxicology Services Business Unit to<BR>
 Support Growing Toxicology Business and Broaden Scientific Talent</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">WEST LAFAYETTE, Ind., May 1, 2019
--&nbsp;<B><U>Bioanalytical Systems, Inc</U>.</B>,&nbsp;(NASDAQ:BASI) (&ldquo;BASi&rdquo; or the &ldquo;Company&rdquo;) today
announced its acquisition of the <B>Smithers Avanza Toxicology Services</B> business unit, a contract research organization (CRO)
located in Gaithersburg, Maryland, which specializes in general toxicology, vaccine safety and developmental and reproductive
toxicology (DART) studies, in support of pharmaceutical and chemical industry research and development. The acquired business
will operate as a wholly owned subsidiary of BASi under the name BASi Gaithersburg.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: #FEFEFE">&ldquo;The
acquisition of the Smithers Avanza Toxicology Services business unit solidly supports BASi&rsquo;s vision of strategic growth,&rdquo;
</FONT>said Robert Leasure, Jr., BASi&rsquo;s President and Chief Executive Officer. &ldquo;<FONT STYLE="background-color: #FEFEFE">With
strong demand for our toxicology and drug disposition services, we needed to add space and talent. </FONT>The team that is joining
us from Smithers in Gaithersburg will allow us to provide more resources to our clients, while remaining small enough to be flexible,
responsive and consultative. Not only will the Gaithersburg site provide increased capacity for routine safety assessment, we also
acquired significant expertise in developmental and reproductive toxicology.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Michael Hochschwender, President and Chief Executive Officer,
The Smithers Group, Inc., commented, &ldquo;Selling a business unit is never an easy decision, but we recognized that the scope
and scale of BASi coupled with our team&rsquo;s scientific expertise would benefit our clients and team tremendously. Operating
as a single site toxicology business presented operational efficiency challenges that could be overcome with the added sites and
in-house capabilities of BASi. We are very proud of the accomplishments and reputation of the Gaithersburg Toxicology Services
team. We are thankful to our loyal clients who supported this business and are confident they will enjoy a seamless transition
to BASi.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BASi provides contract research services and monitoring instruments
to emerging pharmaceutical companies, drug development companies, and medical research organizations&mdash;primarily in drug discovery
and development, and integrating services across commercial and academic settings. The acquisition of the Smithers Avanza Toxicology
Services business unit is another strategic milestone for the Company which made several key appointments to its organizational
leadership in recent months, invested in the multi-phase expansion of its GLP toxicology facility near Evansville, Indiana, and
acquired the Missouri-based <B><U>Seventh Wave Laboratories</U></B> in July of last year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">With this transaction, BASi adds immediate
capacity and expects to further capitalize on its assets and broadened scientific expertise to guide clients through drug safety
and disposition evaluations utilizing a comprehensive portfolio of tools and services:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>Lead optimization through candidate selection;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>In vivo toxicology and pharmacology;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>Vaccine safety testing;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>Developmental and Reproductive Toxicology (DART);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>GLP in vivo services;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>GLP and non-GLP/discovery bioanalysis;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>Histopathology including immunohistochemistry and image analysis;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>Drug Metabolism &amp; Pharmacokinetics;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>In vitro and in vivo bioequivalence testing; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>BASi Culex<SUP>&reg;</SUP>&nbsp;Automated Sampling Systems.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: #FEFEFE">Michael Dorato, PhD,
DABT, Fellow ATS, former Executive Vice President of Smithers Avanza Toxicology Services and newly-appointed Senior Vice President
at BASi Gaithersburg, added, &ldquo;Our group strengthens BASi&rsquo;s core capabilities, adds scientific depth, and expands the
offerings, all while providing a moderate-sized CRO experience, focused on clients that value flexibility and responsiveness.&rdquo;
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Transaction Summary</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of an asset purchase
agreement (the &ldquo;APA&rdquo;), BASi acquired substantially all of the assets used by the seller in connection with the performance
of in-vivo mammalian toxicology CRO services for pharmaceuticals (small molecules and biologics), vaccines, agro and industrial
chemicals for approximately $1.27 million in cash (a portion of which remains in escrow), 200,000 Common Shares of BASi and an
unsecured subordinated promissory note in the initial principal amount of $810,000. In connection with the transaction, BASi amended
its credit arrangements with First Internet Bank to, among other things, renew the Company&rsquo;s revolving loan of $3.5 million
and to add two new term loans in the amounts of $1.27 million and $1.1 million, respectively, a portion of the proceeds of which
were used to fund the acquisition, with the remaining proceeds to be used for capital equipment financing and for future general
corporate needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Current Report on Form 8-K containing
further details regarding the APA and the transaction will be filed by BASi.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Bioanalytical Systems, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BASi is a pharmaceutical development company providing contract
research services and monitoring instruments to emerging pharmaceutical companies and the world's leading drug development companies
and medical research organizations. The Company focuses on developing innovative services supporting its clients&rsquo; discovery
and development objectives for improved decision-making and accelerated goal attainment. BASi&rsquo;s products focus on increasing
efficiency, improving data, and reducing the cost of taking new drugs to market. Visit&nbsp;www.BASinc.com&nbsp;for more information
about BASi.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This release may contain forward-looking statements that
are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market
and demand for our products and services, the development, marketing and sales of products and services, changes in technology,
industry and regulatory standards, and various market and operating risks detailed in the company's filings with the U.S. Securities
and Exchange Commission.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I></I></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !0 *H# 2(  A$! Q$!_\0
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M<ZEJ)U&TUBXNAJDZI+!YYC50_ RIV\5VOAOPW:^&[:ZAMCN$]PTN<=%Z*OT
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M\@QP?O8Q^%;+7W]CW&IQ3,63;]I@W$G.>"OM\V./>K-]I#WGB'2=3$P5; 3
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !I G # 2(  A$! Q$!_\0
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M>VMY](L9(;48@C:!2L8]%&.![5+<:)I5W#<0W&G6LL=RRO,K1 B1E "D^I
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M9P3W37TC>9/+/\ZQICH &49.<]!TS7HLWA;0)XH(I=%T]X[<,L2-;J0@8Y(
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MC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,9IMDSP6(A%RE!I(V:*X+7/B[X<\/ZW=:3>1:@;BV8*YBA4KD@'@[AV-9_\
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M>HZ5!_PL;1/^>=Y_WZ'^-'_"QM$_YYWG_?H?XU@Z&)<G+D9UK'X)+E]HOO\
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M  ('_P 31];IA]6F?.-%?1W_  HOPC_STU/_ ,"!_P#$T?\ "B_"/_/34_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BN8S+:RQKC<
MZ%1GU(J6B@#B;+P=<06C^;':&Z+Z<5E!R0(!'NYQD?=?'U[9J"X\#73Z-;6L
M M(IUBNEF89 D,DBN%8@9*G&&^O>N]HK3VLB.1'$3>&]7EN;K5[.VLK#4 \1
MM8!)E!M1T=F8+U97[#_EFGX0OX-OX=8LEMH[?[!:RVA23<%8QQ##!QM)9B2Q
M'S 8/KG/>T4>TD'(CA+3P?J,6GA-EI#<V]I"EN5;*^?%,\BL>. <C/?DU6N?
M!&HO*S?NYFO8$%R1.$$<WF-)(PRA8@EQC:5/R#ZCT2BCVL@]FC(\0:=<ZA#8
M?9@C/;7T-PRNVW*JW.#CK@TW7-/O)[G3=0L%CDN+"9G\F5MHD5D*, V#AN<@
M^V.];-%2I-%6.,U30]<U<R33Q64;S6EY;B)9#^Z$BQA-S8^<YC.3QC<,9Q5)
M_!FI/<7J,4<.UY)'</.!N,R.JJ5";N-X!RQ&%&!TQZ!15*HUL2X)G&W/A.6.
M6)[.TL_+B2Q'E<*&,+N6[?W6&#WQCBM:ZT$WGB<ZC+)*L"VB0J(;AXV+!V8Y
M"D9&".OO6Y12YV/E1Y[<>"]4NM/&FJMI;O"UTXU(.3)<>:' 5@!D9WC=R?NC
M'MHC2-434+358-%TZVD@F^:UAGP74Q%-Q;;C()&!C[H_"NQHI^T8N1'G47@S
M646R0"TBF$"1SW"OO52-^2%9<AEW_*RE>ISTY6T\&ZK#!;R/! TEI]F7[.]P
M"ERL18D<( !\V5R"<CG%>B44_:R#V:,/PSIESIMO?FY@M[=KJ]DN5A@;<J*P
M7@G YX)..YJWHMC-I]G/%,5+/=SS#:<_*\K,/QP16C14.3925CSRX\!Z@VCV
MMO%=9F%K+#,LMPS(K%U8; 00H.TJ<#HW0]*CGTZXT/4+34[VS65)9YB]O*_F
M(I,2*'+*FU7^0C&WD$\YZ^CT5?M7U)]FNAYIIGAO6SX:%M#8VT2W]I;HPDD,
M?V?9*[$;=N3E6&.F#UQ4NK^#]<NSJ$,,=J8[A[ORI/-"LOFNK L2A.WC!5<'
M(SGT]&HH]K*]Q>S5K'%R>&[^'53?1V5I<)%J$URL#2;1,LD84-]W =3GKG@G
MFJ?_  B7V#2+^;4?L\?^@A8GA5G-M()I955 !G:I>,#'7;T%>@44O:2'R(X]
M=#O[[P)<PRPI'JNI,+NXC+E LC,K;-W4;5 4'_9%5]2\,ZEJUI!"MM%;?9W>
M;=<7LEPTW 'DEB,B-\88>@'%=Q1251H.1'!W7A34KNUU*Q^RV,;7,MQ/'J#2
M$R1^8A 0 #/&=F<XVCIV$9\(:I+$\BPQ0R22X:-[@-A?LTL.[Y45>#(. ,D+
MUZ"O0**?M9![-'GT7@_5/MJ-*J;7>WF+BX'[DQQ*FP#9N/*G&& (8Y'7,LG@
MNZAM-,6T@LP;2SMHYH0=JW#Q2(Y4G'0X;!/?J.37>44>UD'LT<!J7A/4[R1;
MF.RM(1-#<0O9PS!40R,#O)*')('S;0#Z9KN;2 VUE! 6+&*-4W$DDX&.IJ:B
)IE-R5F-12/_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
